11:40 AM EDT, 06/18/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Tuesday it has randomized the first patient in a phase 3 clinical trial of brenetafusp in combination with nivolumab to treat first-line advanced or metastatic cutaneous melanoma, a type of skin cancer.

The trial will randomize patients with first-line advanced or metastatic cutaneous melanoma to brenetafusp plus nivolumab versus a control arm of either nivolumab or nivolumab plus relatlimab, depending on country, the company said. Bristol-Myers Squibb ( BMY ) will provide nivolumab, Immunocore ( IMCR ) said.

Immunocore ( IMCR ) is continuing to enroll patients into a phase 1/2 trial in monotherapy and combination arms across multiple tumor types, it said.

The company's shares were down more than 2% in recent trading.

Price: 35.93, Change: -1.06, Percent Change: -2.87